Free Trial
→ Nvidia Times 1,000,000 (From Paradigm Press) (Ad)tc pixel

PureTech Health (LON:PRTC) Trading Up 14.2% - Should You Buy?

Written by MarketBeat
Updated September 22, 2025
PureTech Health logo with Medical background

Key Points

  • PureTech Health shares surged 14.2%, closing at GBX 121.50 ($1.64) after reaching a peak of GBX 123.80 ($1.67), with trading volume increasing by 1,053% compared to the average.
  • Insider Bharatt Chowrira purchased 167,739 shares at an average cost of GBX 1 per share, indicating confidence from current management with insiders holding 13.13% of the stock.
  • The company focuses on developing medicines for various diseases and has a market cap of £293.65 million, highlighting its clinical-stage biopharma status.
  • Five stocks we like better than PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price shot up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Price Performance

The stock has a 50 day simple moving average of GBX 129.46 and a two-hundred day simple moving average of GBX 129.72. The company has a market cap of £300.17 million, a price-to-earnings ratio of 730.59 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

Insider Buying and Selling

In related news, insider Bharatt Chowrira bought 167,739 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, with a total value of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

See Also

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.